3.05
price up icon8.16%   0.23
pre-market  시장 영업 전:  3.20   0.15   +4.92%
loading
전일 마감가:
$2.82
열려 있는:
$2.88
하루 거래량:
1.28M
Relative Volume:
1.09
시가총액:
$195.58M
수익:
$488.00K
순이익/손실:
$-41.44M
주가수익비율:
-3.2796
EPS:
-0.93
순현금흐름:
$-31.47M
1주 성능:
+3.74%
1개월 성능:
-18.67%
6개월 성능:
+8.54%
1년 성능:
-30.05%
1일 변동 폭
Value
$2.87
$3.08
1주일 범위
Value
$2.73
$3.08
52주 변동 폭
Value
$2.01
$5.6395

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name
명칭
Cardiff Oncology Inc
Name
전화
858-952-7570
Name
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Name
직원
33
Name
트위터
@cardiffoncology
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
CRDF's Discussions on Twitter

CRDF을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CRDF
Cardiff Oncology Inc
3.05 195.58M 488.00K -41.44M -31.47M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-09-06 개시 Craig Hallum Buy
2022-01-05 개시 William Blair Outperform
2021-12-08 개시 Robert W. Baird Outperform
2021-08-09 재개 Maxim Group Buy
2020-10-22 개시 H.C. Wainwright Buy
2020-10-08 개시 Piper Sandler Overweight
모두보기

Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스

pulisher
Apr 22, 2025

A closer look at Cardiff Oncology Inc (CRDF) is warranted - uspostnews.com

Apr 22, 2025
pulisher
Apr 16, 2025

Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap touched US$186m last week, benefiting both individual investors who own 56% as well as institutions - simplywall.st

Apr 16, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing R - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Announces Completion of Enrollment in Phase 2 C - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial i - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CRDF Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial in Colorectal Cancer | CRDF Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Awards Strategic Compensation Package: Inside the Latest Employee Stock Options Grant - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Major Progress: First-line Colorectal Cancer Treatment Trial Hits Key Milestone - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

Cardiff Oncology announces positive colorectal data and $40m stock oversubscription - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Piper Sandler raises Cardiff Oncology stock target to $10 By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Raymond James Financial Inc. Takes Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 14, 2025
pulisher
Apr 14, 2025

American Century Companies Inc. Raises Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 14, 2025
pulisher
Apr 11, 2025

Metastatic Prostate Cancer Market Future Business - openPR.com

Apr 11, 2025
pulisher
Apr 05, 2025

HighTower Advisors LLC Grows Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 05, 2025
pulisher
Apr 03, 2025

Lucid Capital Markets sets $14 target on Cardiff Oncology stock By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Cardiff Oncology Inc (CRDF) Has A Gold Mine On Its Hands - stocksregister.com

Apr 03, 2025
pulisher
Apr 01, 2025

Charles Schwab Investment Management Inc. Sells 19,629 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 01, 2025
pulisher
Mar 26, 2025

Is Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5? - Insider Monkey

Mar 26, 2025
pulisher
Mar 24, 2025

Bank of New York Mellon Corp Increases Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Mar 24, 2025
pulisher
Mar 21, 2025

10 Hot Biotech Stocks Under $5 - Insider Monkey

Mar 21, 2025
pulisher
Mar 12, 2025

Is Cardiff Oncology 15% bump due to positive clinical trials or a short squeeze? - Mugglehead

Mar 12, 2025
pulisher
Mar 10, 2025

Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: Wha - GuruFocus.com

Mar 10, 2025
pulisher
Mar 10, 2025

Future Industry Growth Of Metastatic Prostate Cancer Market - openPR

Mar 10, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Buys 10,290 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve

Mar 08, 2025
pulisher
Mar 08, 2025

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - Canada NewsWire

Mar 08, 2025
pulisher
Mar 05, 2025

Cardiff Oncology’s Earnings Call: Optimism Amid Challenges - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy - Nasdaq

Mar 04, 2025
pulisher
Mar 03, 2025

Q1 Earnings Forecast for CRDF Issued By William Blair - Defense World

Mar 03, 2025
pulisher
Mar 03, 2025

Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $17.00 - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

HC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) Stock - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Cardiff Oncology Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 01, 2025
pulisher
Feb 28, 2025

Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Cardiff Oncology plans mixed shelf offering - MSN

Feb 28, 2025
pulisher
Feb 28, 2025

Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Call Highlights: Financial Fortification and ... - Yahoo Finance

Feb 28, 2025
pulisher
Feb 27, 2025

Cardiff Oncology Highlights Progress in Cancer Trials - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cardiff Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings call transcript: Cardiff Oncology Q4 2024 highlights strategic advances - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

Cardiff Oncology Reports Positive Initial Efficacy Data for Onvansertib in Metastatic Colorectal Cancer and Secures $40 Million Financing - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Cardiff Oncology, Inc. SEC 10-K Report - TradingView

Feb 27, 2025

Cardiff Oncology Inc (CRDF) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Cardiff Oncology Inc 주식 (CRDF) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Levine James E.
Chief Financial Officer
Dec 18 '24
Buy
5.00
2,400
12,000
67,716
Levine James E.
Chief Financial Officer
Dec 16 '24
Buy
3.83
2,564
9,820
62,564
TANNENBAUM RENEE P
Director
Dec 12 '24
Buy
3.42
10,000
34,224
20,000
PACE GARY W
Director
Dec 11 '24
Buy
2.60
350,115
910,299
1,047,876
PACE GARY W
Director
Dec 11 '24
Buy
2.60
11,500
29,900
1,059,376
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
자본화:     |  볼륨(24시간):